|
Document and Entity Information
|
9 Months Ended |
|---|---|
|
Sep. 30, 2015
|
|
| Document Information [Line Items] | |
| Document Type | 6-K |
| Amendment Flag | false |
| Document Period End Date | Sep. 30, 2015 |
| Document Fiscal Year Focus | 2015 |
| Document Fiscal Period Focus | Q3 |
| Trading Symbol | ICLR |
| Entity Registrant Name | ICON PLC |
| Entity Central Index Key | 0001060955 |
| Current Fiscal Year End Date | --12-31 |
| X | ||||||||||
|
- Definition
If the value is true, then the document is an amendment to previously-filed/accepted document. No definition available.
|
| X | ||||||||||
|
- Definition
End date of current fiscal year in the format --MM-DD. No definition available.
|
| X | ||||||||||
|
- Definition
This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY. No definition available.
|
| X | ||||||||||
|
- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD. No definition available.
|
| X | ||||||||||
|
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other". No definition available.
|
| X | ||||||||||
|
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Trading symbol of an instrument as listed on an exchange. No definition available.
|
| X | ||||||||||
|
- Definition
Noncurrent capital government grants, which are amortized and recognized in earnings over the grant period. No definition available.
|
| X | ||||||||||
|
- Definition
Capital Redemption Reserve No definition available.
|
| X | ||||||||||
|
- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Amount of investments in debt securities classified as available-for-sale, expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards expected to be realized or consumed within one year or operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount after allocation of valuation allowances of noncurrent deferred tax asset attributable to deductible temporary differences and carryforwards. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of deferred tax liability attributable to taxable temporary differences, net of deferred tax asset attributable to deductible temporary differences and carryforwards net of valuation allowances expected to be realized or consumed within one year or operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of deferred tax liability attributable to taxable temporary differences, net of deferred tax asset attributable to deductible temporary differences and carryforwards net of valuation allowances expected to be realized or consumed after one year (or the normal operating cycle, if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Carrying amount due after one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The sum of amounts currently receivable other than from customers. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Aggregate carrying amount of current liabilities (due within one year or within the normal operating cycle if longer) not separately disclosed in the balance sheet. Includes costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Condensed Consolidated Balance Sheets (Parenthetical) (EUR €)
|
Sep. 30, 2015
|
Dec. 31, 2014
|
|---|---|---|
| Ordinary shares, par value | € 0.06 | € 0.06 |
| Ordinary shares, shares authorized | 100,000,000 | 100,000,000 |
| Ordinary shares, shares issued | 57,234,463 | 60,106,780 |
| Ordinary shares, shares outstanding | 57,234,463 | 60,106,780 |
| X | ||||||||||
|
- Definition
Face amount or stated value per share of common stock. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Condensed Consolidated Statements of Operations (USD $)
In Thousands, except Share data, unless otherwise specified |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
|
Sep. 30, 2015
|
Sep. 30, 2014
|
Sep. 30, 2015
|
Sep. 30, 2014
|
|
| Revenue: | ||||
| Gross revenue | $ 557,095 | $ 519,127 | $ 1,584,559 | $ 1,502,075 |
| Reimbursable expenses | (162,354) | (131,538) | (412,930) | (388,832) |
| Net revenue | 394,741 | 387,589 | 1,171,629 | 1,113,243 |
| Costs and expenses: | ||||
| Direct costs | 226,555 | 229,963 | 679,593 | 673,291 |
| Selling, general and administrative expense | 82,435 | 84,466 | 243,310 | 251,036 |
| Depreciation and amortization | 14,366 | 13,737 | 42,535 | 38,207 |
| Total costs and expenses | 323,356 | 328,166 | 965,438 | 962,534 |
| Income from operations | 71,385 | 59,423 | 206,191 | 150,709 |
| Interest income | 531 | 267 | 1,026 | 874 |
| Interest expense | (1,178) | (158) | (1,686) | (712) |
| Income before provision for income taxes | 70,738 | 59,532 | 205,531 | 150,871 |
| Provision for income taxes | (9,196) | (9,216) | (29,534) | (23,577) |
| Net income | $ 61,542 | $ 50,316 | $ 175,997 | $ 127,294 |
| Net income per Ordinary Share: | ||||
| Basic | $ 1.05 | $ 0.81 | $ 2.95 | $ 2.06 |
| Diluted | $ 1.02 | $ 0.79 | $ 2.85 | $ 2.01 |
| Weighted average number of Ordinary Shares outstanding: | ||||
| Basic | 58,659,782 | 61,878,429 | 59,728,608 | 61,863,332 |
| Diluted | 60,369,898 | 63,442,607 | 61,785,849 | 63,434,260 |
| X | ||||||||||
|
- Definition
Revenue earned during the period arising from products sold or services provided under the terms of a contract, not elsewhere specified in the taxonomy. May include government contracts, construction contracts, and any other contract related to a particular project or product. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Cost associated with reimbursable income. This occurs when a services entity incurs expenses on behalf of the client and passes through the cost of reimbursable expenses to a client. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Total costs of sales and operating expenses for the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Sum of operating profit and nonoperating income or expense before Income or Loss from equity method investments, income taxes, extraordinary items, and noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of the cost of borrowed funds accounted for as interest expense for debt. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The net result for the period of deducting operating expenses from operating revenues. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Payments for Share Repurchase Costs No definition available.
|
| X | ||||||||||
|
- Definition
Proceeds From Stock Options And Restricted Shares Exercised No definition available.
|
| X | ||||||||||
|
- Definition
Amortization of Government Grants. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of deferred income tax expense (benefit) and income tax credits. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of cash inflow from realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The increase (decrease) during the reporting period in other current operating liabilities not separately disclosed in the statement of cash flows. No definition available.
|
| X | ||||||||||
|
- Definition
The increase (decrease) during the reporting period in other noncurrent operating assets not separately disclosed in the statement of cash flows. No definition available.
|
| X | ||||||||||
|
- Definition
The increase (decrease) during the reporting period in other noncurrent operating liabilities not separately disclosed in the statement of cash flows. No definition available.
|
| X | ||||||||||
|
- Definition
The increase (decrease) during the reporting period in other amounts due to the reporting entity, which are not otherwise defined in the taxonomy. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The increase (decrease) during the reporting period of the amount of revenue for work performed for which billing has not occurred, net of uncollectible accounts. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cash outflow to reacquire common stock during the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cash outflow for cost incurred directly with the issuance of an equity security. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Condensed Consolidated Statements of Shareholders' Equity and Comprehensive Income (USD $)
In Thousands, except Share data, unless otherwise specified |
Total
|
Ordinary Shares
|
Additional Paid-in Capital
|
Capital Redemption Reserve
|
Accumulated Other Comprehensive Income
|
Retained Earnings
|
|---|---|---|---|---|---|---|
| Balance at Dec. 31, 2014 | $ 950,206 | $ 5,037 | $ 327,234 | $ 305 | $ (37,555) | $ 655,185 |
| Balance (in shares) at Dec. 31, 2014 | 60,106,780 | 60,106,780 | ||||
| Comprehensive Income: | ||||||
| Net income | 175,997 | 175,997 | ||||
| Currency translation adjustment | (29,914) | (29,914) | ||||
| Currency impact of long term funding | 12,236 | 12,236 | ||||
| Tax on currency impact of long term funding | (3,175) | (3,175) | ||||
| Unrealized capital gain - investments | 215 | 215 | ||||
| Total comprehensive income | 155,359 | (20,638) | 175,997 | |||
| Exercise of share options (in shares) | 686,467 | |||||
| Exercise of share options | 18,360 | 46 | 18,314 | |||
| Issue of restricted share units (in shares) | 227,805 | |||||
| Issue of restricted share units | 15 | 15 | ||||
| Share issuance costs | (6) | (6) | ||||
| Non-cash stock compensation expense | 24,043 | 24,043 | ||||
| Repurchase of ordinary shares (in shares) | (3,786,589) | |||||
| Repurchase of ordinary shares | (286,923) | (251) | 251 | (286,923) | ||
| Share repurchase costs | (802) | (802) | ||||
| Tax benefit on exercise of options | 3,014 | 3,014 | ||||
| Balance at Sep. 30, 2015 | $ 863,266 | $ 4,832 | $ 372,614 | $ 556 | $ (58,193) | $ 543,457 |
| Balance (in shares) at Sep. 30, 2015 | 57,234,463 | 57,234,463 |
| X | ||||||||||
|
- Definition
Adjustment to Retained Earning Share Repurchase costs No definition available.
|
| X | ||||||||||
|
- Definition
Adjustment that results from the process of translating the impact of long-term funding into the functional currency of the reporting entity. No definition available.
|
| X | ||||||||||
|
- Definition
Tax impact on the adjustment that results from the process of translating the impact of long-term funding into the functional currency of the reporting entity. No definition available.
|
| X | ||||||||||
|
- Definition
This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation". Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of increase in additional paid in capital (APIC) resulting from a tax benefit associated with share-based compensation plan other than an employee stock ownership plan (ESOP). Includes, but is not limited to, excess tax benefit. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Number of share options (or share units) exercised during the current period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Value of stock issued as a result of the exercise of stock options. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Basis of Presentation
|
9 Months Ended |
|---|---|
|
Sep. 30, 2015
|
|
| Basis of Presentation |
1. Basis of Presentation
These
condensed consolidated financial statements, which have been
prepared in accordance with United States generally accepted
accounting principles (“US GAAP”), have not been
audited. The condensed consolidated financial statements reflect
all adjustments, which are, in the opinion of management, necessary
to present a fair statement of the operating results and financial
position for the periods presented. The preparation of the
condensed consolidated financial statements in conformity with US
GAAP requires management to make estimates and assumptions that
affect reported amounts and disclosures in the condensed
consolidated financial statements. Actual results could differ from
those estimates.
The
condensed consolidated financial statements should be read in
conjunction with the accounting policies and notes to the
consolidated financial statements included in ICON’s Form
20-F for the year ended December 31, 2014. Operating results for
the nine months ended September 30, 2015 are not necessarily
indicative of the results that may be expected for the fiscal
period ending December 31, 2015.
|
| X | ||||||||||
|
- Definition
The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Goodwill
|
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2015
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Goodwill |
2. Goodwill
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure for goodwill. No definition available.
|
|
Business Combinations
|
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2015
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Combinations |
3. Business Combinations
Acquisitions - MediMedia Pharma Solutions.
On
February 27, 2015 the Company acquired MediMedia Pharma Solutions
for a total cash consideration of $120.0 million including certain
payments to be made on behalf of the company on completion
totalling $14.9 million. Headquartered in Yardley, Pennsylvania,
MediMedia Pharma Solutions includes MediMedia Managed Markets and
Complete Healthcare Communications. MediMedia Managed Markets is a
leading provider of strategic payer-validated market access
solutions. Complete Healthcare Communications is one of the leading
medical and scientific communication agencies working with medical
affairs, commercial and brand development teams within life science
companies. The acquisition agreement also provides for certain
working capital targets to be achieved by MediMedia Pharma
Solutions on acquisition. The Company has withheld a provisional
amount of $3.6 million on acquisition pending completion of this
review. During the three months ended September 30, 2015 a further
$383,000 was returned to the Company on completion of the
review.
The
acquisition of MediMedia Pharma Solutions has been accounted for as
a business combination in accordance with FASB ASC 805 Business
Combinations. The following table summarizes the Company’s
provisional estimates of the fair values of the assets acquired and
liabilities assumed:
Prior Period Acquisitions – Aptiv Solutions
On
May 7, 2014 the Company acquired 100% of the common stock of Aptiv
Solutions (“Aptiv”), a global biopharmaceutical and
medical device development services company and leader in adaptive
clinical trials for a cash consideration of $143.5 million
including certain payments to be made on behalf of the company on
completion totalling $22.4 million. Aptiv offers full-service
clinical trial consulting and regulatory support for drugs, medical
devices and diagnostics with a specific focus on strategy to
increase product development efficiency and productivity. It is a
market leader in the integrated design and execution of adaptive
clinical trials for exploratory and late phase development as well
as being an industry leader in medical device and diagnostic
development in key medical technology segments. The acquisition
agreement also provided for certain working capital targets to be
achieved by Aptiv on completion. On March 25, 2015 the Company
received $1.9 million on completion of this review.
The acquisition of Aptiv Solutions has been accounted for as a
business combination in accordance with FASB ASC 805 Business
Combinations. The following table summarizes the preliminary
estimated fair values of the assets acquired and the liabilities
assumed:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Income Taxes
|
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2015
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Income Taxes |
4. Income Taxes
Income
taxes recognized during the three and nine months ended September
30, 2015 comprise:
As
at September 30, 2015 the Company maintains a $28.6 million
liability (December 31, 2014: $25.6 million) for unrecognized tax
benefit, which is comprised of $25.6 million (December 31, 2014:
$23.2 million) related to items generating unrecognized tax
benefits and $3.0 million (December 31, 2014: $2.4 million) for
interest and related penalties to such items. The Company
recognizes interest accrued on unrecognized tax benefits as an
additional income tax expense.
The
Company has analyzed filing positions in all of the significant
federal, state and foreign jurisdictions where it is required to
file income tax returns, as well as open tax years in these
jurisdictions. The only periods subject to examination by the major
tax jurisdictions where the Company does business are 2009 through
2014 tax years. The Company does not believe that the outcome of
any examination will have a material impact on its financial
statements.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Net income per ordinary share
|
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2015
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Net income per ordinary share |
5. Net income per ordinary share
Basic
net income per ordinary share has been computed by dividing net
income available to ordinary shareholders by the weighted average
number of ordinary shares outstanding during the period. Diluted
net income per ordinary share is computed by adjusting the weighted
average number of ordinary shares outstanding during the period for
all potentially dilutive ordinary shares outstanding during the
period and adjusting net income for any changes in income or loss
that would result from the conversion of such potential ordinary
shares. There is no difference in net income used for basic and
diluted net income per ordinary share.
The
reconciliation of the number of shares used in the computation of
basic and diluted net income per ordinary share is as
follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure for earnings per share. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Share-based Awards
|
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2015
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Share-based Awards |
6. Share-based Awards
Share Options
On
July 21, 2008 the Company adopted the Employee Share Option Plan
2008 (the “2008 Employee Plan”) pursuant to which the
Compensation and Organization Committee of the Company’s
Board of Directors may grant options to any employee, or any
director holding a salaried office or employment with the Company
or a Subsidiary for the purchase of ordinary shares. On the same
date, the Company also adopted the Consultants Share Option Plan
2008 (the “2008 Consultants Plan”), pursuant to which
the Compensation and Organization Committee of the Company’s
Board of Directors may grant options to any consultant, adviser or
non-executive director retained by the Company or any Subsidiary
for the purchase of ordinary shares.
Each
option granted under the 2008 Employee Plan or the 2008 Consultants
Plan (together the “2008 Option Plans”) will be an
employee stock option, or NSO, as described in Section 422 or 423
of the Internal Revenue Code. Each grant of an option under the
2008 Options Plans will be evidenced by a Stock Option Agreement
between the optionee and the Company. The exercise price will be
specified in each Stock Option Agreement, however option prices
will not be less than 100% of the fair market value of an ordinary
share on the date the option is granted.
An
aggregate of 6.0 million ordinary shares have been reserved under
the 2008 Employee Plan, as reduced by any shares issued or to be
issued pursuant to options granted under the 2008 Consultants Plan,
under which a limit of 400,000 shares applies. Further, the maximum
number of ordinary shares with respect to which options may be
granted under the 2008 Employee Option Plan, during any calendar
year to any employee shall be 400,000 ordinary shares. There is no
individual limit under the 2008 Consultants Plan. No options may be
granted under the 2008 Option Plans after July 21,
2018.
On
January 17, 2003 the Company adopted the Share Option Plan 2003
(the “2003 Share Option Plan”) pursuant to which the
Compensation and Organization Committee of the Board could grant
options to officers and other employees of the Company or its
subsidiaries for the purchase of ordinary shares. An aggregate of
6.0 million ordinary shares were reserved under the 2003 Share
Option Plan; and, in no event could the number of ordinary shares
issued pursuant to options awarded under this plan exceed 10% of
the outstanding shares, as defined in the 2003 Share Option Plan,
at the time of the grant, unless the Board expressly determined
otherwise. Further, the maximum number of ordinary shares with
respect to which options could be granted under the 2003 Share
Option Plan during any calendar year to any employee was 400,000
ordinary shares. The 2003 Share Option Plan expired on January 17,
2013. No new options may be granted under this plan.
Share
option awards are granted with an exercise price equal to the
market price of the Company’s shares at date of grant. Share
options typically vest over a period of five years from date of
grant and expire eight years from date of grant. The maximum
contractual term of options outstanding at September 30, 2015 is
eight years.
The
following table summarizes option activity for the nine months
ended September 30, 2015:
The
Company has outstanding options with fair values ranging from $5.88
to $19.78 per option or a weighted average fair value
of $11.91
per option. The Company issues ordinary shares for
all options exercised. The total amount of fully vested share
options which remained outstanding at September 30, 2015, was
695,902. Fully vested share options at September 30, 2015, have an
average remaining contractual term of 3.51 years, an average
exercise price of $25.19 and a total intrinsic value of $31.9
million. The total intrinsic value of options exercised during the
nine months ended September 30, 2015 was $30.5 million (September
30, 2014: $18.2 million).
The
following table summarizes the movement in non-vested share options
for the nine months ended September 30, 2015:
Fair value of Stock Options Assumptions
The
weighted average fair value of options granted during the nine
months ended September 30, 2015 and September 30, 2014 was
calculated using the Black-Scholes option pricing model. The
weighted average fair values and assumptions used were as
follows:
Expected
volatility is based on the historical volatility of our common
stock over a period equal to the expected term of the options; the
expected life represents the weighted average period of time that
options granted are expected to be outstanding given consideration
to vesting schedules and our historical experience of past vesting
and termination patterns. The risk-free rate is based on the U.S.
government zero-coupon bonds yield curve in effect at time of the
grant for periods corresponding with the expected life of the
option.
Restricted Share Units and Performance Share Units
On
July 21, 2008 the Company adopted the 2008 Employees Restricted
Share Unit Plan (the “2008 RSU Plan”) pursuant to which
the Compensation and Organization Committee of the Company’s
Board of Directors may select any employee, or any director holding
a salaried office or employment with the Company, or a Subsidiary
to receive an award under the plan. An aggregate of 1.0 million
ordinary shares have been reserved for issuance under the 2008 RSU
Plan.
On
April 23, 2013 the Company adopted the 2013 Employees Restricted
Share Unit Plan (the “2013 RSU Plan”) pursuant to which
the Compensation and Organization Committee of the Company’s
Board of Directors may select any employee, or any director holding
a salaried office or employment with the Company, or a Subsidiary
to receive Restricted Share Units (“RSUs”) and/or
Performance Share Units (“PSUs”) under the plan. An
aggregate of 1.6 million ordinary shares have been reserved for
issuance under the 2013 RSU Plan. The shares are awarded at zero
cost and vest over a service period. Awards under the 2013 RSU Plan
may be settled in cash or shares at the option of the
Company.
The
Company has awarded RSUs and PSUs to certain key individuals of the
Group. The following table summarizes RSU and PSU activity for the
nine months ended September 30, 2015:
PSUs
were awarded to certain key executives of the Company during the
period ended September 30, 2015. PSUs vest based upon both a
service basis and performance basis. The performance element is
contingent upon cumulative EPS performance of the Company over a
three year period (i.e. for the three year financial period ending
December 31, 2018). PSUs with similar EPS performance targets were
awarded during the years ended December 31, 2013 and December 31,
2014. 467,991 of the 936,418 PSUs outstanding at September 30, 2015
vest upon the achievement of EPS performance targets.
Non-cash stock compensation expense
Non-cash
stock compensation expense for the three and nine months ended
September 30, 2015 has been allocated as follows:
Total
non-cash stock compensation expense not yet recognized at September
30, 2015 amounted to $57.7 million. The weighted average period
over which this is expected to be recognized is 2.5 years. Total
tax benefit recognized in additional paid in capital related to the
non-cash compensation expense amounted to $3.0 million for the nine
months ended September 30, 2015 (September 30, 2014: $1.8
million).
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Share Capital
|
9 Months Ended |
|---|---|
|
Sep. 30, 2015
|
|
| Share Capital |
7. Share Capital
Share Repurchase Program
On
May 1, 2015 the Company commenced a buyback program of up to $60
million under which the Company could acquire its outstanding
ordinary shares (by way of redemption), in accordance with Irish
law, the United States securities laws and the Company’s
constitutional documents through open market share
acquisitions.
The
buyback program gave a broker authority to acquire the
Company’s ordinary shares from time to time on the open
market in accordance with agreed terms and limitations. The
acquisition of shares pursuant to the buyback program was effected
by way of redemption and cancellation of the shares, in accordance
with the Constitution of the Company.
During
the three months ended June 30, 2015, 882,419 ordinary shares were
redeemed by the Company under the buyback program for a total
consideration of $58.2 million. All ordinary shares that were
redeemed under the buyback program were cancelled in accordance
with the Constitution of the Company and the nominal value of these
shares transferred to a capital redemption reserve fund as required
under Irish Company Law.
On
July 31, 2015 the Company commenced a further buyback program of up
to $400 million under which the Company could acquire its
outstanding ordinary shares (by way of redemption), in accordance
with Irish law, the United States securities laws and the
Company’s constitutional documents through open market share
acquisitions.
The
buyback program gives a broker authority to acquire the
Company’s ordinary shares from time to time on the open
market in accordance with agreed terms and limitations. The
acquisition of shares pursuant to the buyback program was effected
by way of redemption and cancellation of the shares, in accordance
with the Constitution of the Company.
During
the three months ended September 30, 2015, 2,904,170 ordinary
shares were redeemed by the Company under the buyback program for a
total consideration of $229.5 million. All ordinary shares that
were redeemed under the buyback program were cancelled in
accordance with the Constitution of the Company and the nominal
value of these shares transferred to a capital redemption reserve
fund as required under Irish Company Law.
|
| X | ||||||||||
|
- Definition
The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Business Segment Information
|
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2015
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Segment Information |
8. Business Segment Information
The
Company determines and presents operating segments based on the
information that is internally provided to the Chief Executive
Officer, Chief Operating Officer and Chief Financial Officer, who
together are considered the Company’s chief operating
decision makers, in accordance with FASB ASC 280-10 Disclosures about Segments of
an Enterprise and Related Information.
The
Company is a contract research organization (“CRO”),
providing outsourced development services on a global basis to the
pharmaceutical, biotechnology and medical device industries. It
specializes in the strategic development, management and analysis
of programs that support all stages of the clinical development
process - from compound selection to Phase I-IV clinical studies.
The Company has the expertise and capability to conduct clinical
trials in most major therapeutic areas on a global basis and has
the operational flexibility to provide development services on a
stand-alone basis or as part of an integrated “full
service” solution. The Company has expanded predominately
through internal growth, together with a number of strategic
acquisitions to enhance its expertise and capabilities in certain
areas of the clinical development process.
The
Company is generally awarded projects based upon responses to
requests for proposals received from companies in the
pharmaceutical, biotechnology and medical device industries or work
orders executed under our strategic partnership arrangements.
Contracts with customer are generally entered into centrally, in
most cases with ICON Clinical Research Limited (“ICON
Ireland”), the Company’s principal operating subsidiary
in Ireland. Revenues, which consist primarily of fees earned under
these contracts, are allocated to individual entities within the
Group, based on where the work is performed in accordance with the
Company’s global transfer pricing model.
ICON
Ireland acts as the group entrepreneur under the Company’s
global transfer pricing model given its role in the development and
management of the group, it’s ownership of key intellectual
property and customer relationships, its key role in the mitigation
of risks faced by the group and its responsibility for maintaining
the Company’s global network. As such it enters into the
majority of the Company’s customer contracts.
ICON
Ireland remunerates other operating entities in the ICON Group on
the basis of a guaranteed cost plus mark up for the services they
perform in each of their local territories. The cost plus mark up
for each ICON entity is established to ensure that each of ICON
Ireland and the ICON entities that are involved in the conduct of
services for customers, earn an appropriate arms-length return
having regard to the assets owned, risks borne, and functions
performed by each entity from these intercompany transactions. The
cost plus mark-up policy is reviewed annually to ensure that it is
market appropriate.
The
geographic split of revenue disclosed for each region outside
Ireland is the cost plus revenue attributable to these entities.
The residual revenues of the Group, once each ICON entity has been
paid its respective intercompany service fee, generally fall to be
retained by ICON Ireland. As such revenues and income from
operations in Ireland are a function of this global transfer
pricing model and comprise net revenues of the Group after
deducting the cost plus revenues attributable to the activities
performed outside Ireland.
The
Company's areas of operation outside of Ireland include the United
States, United Kingdom, France, Germany, Italy, Spain, The
Netherlands, Sweden, Turkey, Poland, Czech Republic, Latvia,
Russia, Ukraine, Hungary, Israel, Romania, Switzerland, Canada,
Mexico, Brazil, Colombia, Argentina, Chile, Peru, India, China,
South Korea, Japan, Thailand, Taiwan, Singapore, The Philippines,
Australia, New Zealand, and South Africa.
Segment
information as at September 30, 2015 and December 31, 2014 and for
the three and nine months ended September 30, 2015 and September
30, 2014 is as follows:
a)
The distribution of net revenue by geographical area was as
follows:
*
All sales shown for Ireland are export sales.
b)
The distribution of income from operations, including restructuring
and other items, by geographical area was as follows:
c)
The distribution of property, plant and equipment, net, by
geographical area was as follows:
d)
The distribution of depreciation and amortization by geographical
area was as follows:
e)
The distribution of total assets by geographical area was as
follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Goodwill (Tables)
|
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2015
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Goodwill |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Business Combinations (Tables)
|
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2015
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
MediMedia Pharma Solutions
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed |
The
following table summarizes the Company’s provisional
estimates of the fair values of the assets acquired and liabilities
assumed:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Aptiv Solutions
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed |
The following table summarizes the preliminary estimated fair
values of the assets acquired and the liabilities
assumed:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Income Taxes (Tables)
|
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2015
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Income Taxes Recognized During Period | Income
taxes recognized during the three and nine months ended September
30, 2015 comprise:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Net income per ordinary share (Tables)
|
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2015
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reconciliation of Number of Shares Used in Computation of Basic and Diluted Net Income Per Ordinary Share | The
reconciliation of the number of shares used in the computation of
basic and diluted net income per ordinary share is as
follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Share-based Awards (Tables)
|
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2015
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Summary of Stock Option Activity | The
following table summarizes option activity for the nine months
ended September 30, 2015:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Summary of Movement in Non-Vested Share Options | The
following table summarizes the movement in non-vested share options
for the nine months ended September 30, 2015:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Weighted Average Fair Values and Assumptions Used | The
weighted average fair values and assumptions used were as
follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RSU and PSU Activity | The following table summarizes RSU and PSU activity for the
nine months ended September 30, 2015:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Non-cash Stock Compensation Expense | Non-cash
stock compensation expense for the three and nine months ended
September 30, 2015 has been allocated as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Schedule of Non Cash Stock Compensation Expense. No definition available.
|
| X | ||||||||||
|
- Definition
Schedule Of Share Based Compensation Restricted Stock Units Performance Stock Units Award Activity [Table Text Block] No definition available.
|
| X | ||||||||||
|
- Definition
Tabular disclosure of the changes in outstanding nonvested shares. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Business Segment Information (Tables)
|
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2015
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Distribution of Net Revenue by Geographical Area |
a)
The distribution of net revenue by geographical area was as
follows:
*
All sales shown for Ireland are export sales.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Distribution of Income from Operations by Geographical Area | b)
The distribution of income from operations, including restructuring
and other items, by geographical area was as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Distribution of Property, Plant and Equipment, Net, by Geographical Area |
c)
The distribution of property, plant and equipment, net, by
geographical area was as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Distribution of Depreciation and Amortization by Geographical Area |
d)
The distribution of depreciation and amortization by geographical
area was as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Distribution of Total Assets by Geographical Area | e)
The distribution of total assets by geographical area was as
follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Operating Income by Geography. No definition available.
|
| X | ||||||||||
|
- Definition
Schedule Of Depreciation And Amortization Expense By Geographical Area. No definition available.
|
| X | ||||||||||
|
- Definition
Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Goodwill (Detail) (USD $)
In Thousands, unless otherwise specified |
9 Months Ended | 12 Months Ended |
|---|---|---|
|
Sep. 30, 2015
|
Dec. 31, 2014
|
|
| Goodwill [Line Items] | ||
| Opening balance | $ 463,324 | $ 357,523 |
| Current period acquisitions (Note 3) | 115,180 | 121,209 |
| Prior period acquisitions | 4,418 | |
| Foreign exchange movement | (7,544) | (15,408) |
| Closing balance | $ 575,378 | $ 463,324 |
| X | ||||||||||
|
- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of increase (decrease) from foreign currency translation adjustments of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Business Combinations - Additional Information (Detail) (USD $)
|
0 Months Ended | 0 Months Ended | 3 Months Ended | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Mar. 25, 2015
Aptiv Solutions
|
May 07, 2014
Aptiv Solutions
|
May 07, 2014
Aptiv Solutions
|
Feb. 27, 2015
MediMedia Pharma Solutions
|
Sep. 30, 2015
MediMedia Pharma Solutions
|
Feb. 27, 2015
MediMedia Pharma Solutions
|
|||||||
| Business Acquisition [Line Items] | ||||||||||||
| Cash consideration | $ 143,500,000 | $ 120,000,000 | ||||||||||
| Contingent cash consideration | 14,900,000 | |||||||||||
| Provisional amount on acquisition pending completion | 3,600,000 | 383,000 | ||||||||||
| Percentage of common stock acquired | 100.00% | |||||||||||
| Adjustments to cash consideration | 22,399,000 | [1] | 11,283,000 | [2] | ||||||||
| Working capital adjustment | $ 1,900,000 | $ 1,964,000 | ||||||||||
|
||||||||||||
| X | ||||||||||
|
- Definition
The working capital adjustment was received in October 2013 however it relates to the purchase of Cross Country Healthcare Inc on 15 February 2013, and is disclosed as part of net assets acquired on this date. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Percentage of voting equity interests acquired at the acquisition date in the business combination. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of liability recognized arising from contingent consideration in a business combination. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to items of consideration transferred in connection with a business combination for which the initial accounting was incomplete. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed of MediMedia Pharma Solutions (Detail) (USD $)
In Thousands, unless otherwise specified |
0 Months Ended | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2015
|
Dec. 31, 2014
|
Dec. 31, 2013
|
Feb. 27, 2015
MediMedia Pharma Solutions
|
Feb. 27, 2015
MediMedia Pharma Solutions
|
|||||||
| Business Acquisition [Line Items] | |||||||||||
| Property, plant and equipment | $ 1,049 | ||||||||||
| Goodwill | 575,378 | 463,324 | 357,523 | 115,180 | [1] | ||||||
| Accounts receivable | 5,240 | ||||||||||
| Unbilled Revenue | 4,324 | ||||||||||
| Prepayments and other current assets | 621 | ||||||||||
| Accounts payable | (749) | ||||||||||
| Payments on account | (4,186) | ||||||||||
| Other liabilities | (16,760) | ||||||||||
| Net assets acquired | 104,719 | ||||||||||
| Cash consideration | 120,000 | ||||||||||
| Adjustments to cash consideration | (11,283) | [2] | |||||||||
| Working capital adjustment | (3,998) | ||||||||||
| Net purchase consideration | $ 104,719 | ||||||||||
|
|||||||||||
| X | ||||||||||
|
- Definition
Business Acquisition Purchase Price Allocation Working Capital No definition available.
|
| X | ||||||||||
|
- Definition
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Payments on Account No definition available.
|
| X | ||||||||||
|
- Definition
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Unbilled Revenue No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of property, plant, and equipment recognized as of the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed of Aptiv Solutions (Detail) (USD $)
In Thousands, unless otherwise specified |
0 Months Ended | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2015
|
Dec. 31, 2014
|
Dec. 31, 2013
|
Mar. 25, 2015
Aptiv Solutions
|
May 07, 2014
Aptiv Solutions
|
May 07, 2014
Aptiv Solutions
|
May 07, 2014
Aptiv Solutions
Customer relationships
|
May 07, 2014
Aptiv Solutions
Order Backlog
|
|||||||
| Business Acquisition [Line Items] | ||||||||||||||
| Property, plant and equipment | $ 6,924 | |||||||||||||
| Goodwill | 575,378 | 463,324 | 357,523 | 125,627 | [1] | |||||||||
| Intangible asset | 21,400 | 7,900 | ||||||||||||
| Cash and cash equivalents | 3,484 | |||||||||||||
| Accounts receivable | 25,091 | |||||||||||||
| Unbilled Revenue | 21,154 | |||||||||||||
| Prepayments and other current assets | 4,180 | |||||||||||||
| Non-current assets | 2,911 | |||||||||||||
| Accounts payable | (9,565) | |||||||||||||
| Other liabilities | (26,782) | |||||||||||||
| Payments on account | (31,094) | |||||||||||||
| Non-current other liabilities | (11,303) | |||||||||||||
| Loan notes payable | (20,790) | |||||||||||||
| Net assets acquired | 119,137 | |||||||||||||
| Cash consideration | 143,500 | |||||||||||||
| Adjustments to cash consideration | (22,399) | [2] | ||||||||||||
| Working capital adjustment | (1,900) | (1,964) | ||||||||||||
| Net assets acquired/Net purchase consideration | $ 119,137 | |||||||||||||
|
||||||||||||||
| X | ||||||||||
|
- Definition
The working capital adjustment was received in October 2013 however it relates to the purchase of Cross Country Healthcare Inc on 15 February 2013, and is disclosed as part of net assets acquired on this date. No definition available.
|
| X | ||||||||||
|
- Definition
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Payments on Account No definition available.
|
| X | ||||||||||
|
- Definition
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Unbilled Revenue No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of identifiable intangible assets recognized as of the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of property, plant, and equipment recognized as of the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Income Taxes Recognized During Period (Detail) (USD $)
In Thousands, unless otherwise specified |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
|
Sep. 30, 2015
|
Sep. 30, 2014
|
Sep. 30, 2015
|
Sep. 30, 2014
|
|
| Reconciliation of Provision of Income Taxes [Line Items] | ||||
| Provision for income taxes | $ 9,196 | $ 9,216 | $ 29,534 | $ 23,577 |
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Income Taxes - Additional Information (Detail) (USD $)
In Millions, unless otherwise specified |
9 Months Ended | |||
|---|---|---|---|---|
|
Sep. 30, 2015
|
Dec. 31, 2014
|
Sep. 30, 2015
Earliest Tax Year
|
Sep. 30, 2015
Latest Tax Year
|
|
| Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items] | ||||
| Liability for unrecognized tax benefit | $ 28.6 | $ 25.6 | ||
| Items generating unrecognized tax benefits | 25.6 | 23.2 | ||
| Interest and related penalties | $ 3.0 | $ 2.4 | ||
| Tax year subject to examination by major tax jurisdictions | 2009 | 2014 | ||
| X | ||||||||||
|
- Definition
Unrecognized Tax Benefits, Current Year Tax Positions No definition available.
|
| X | ||||||||||
|
- Definition
Tax year that remains open to examination under enacted tax laws, in CCYY format. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Amount of unrecognized tax benefits pertaining to uncertain tax positions taken in tax returns. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Reconciliation of Number of Shares Used in Computation of Basic and Diluted Net Income Per Ordinary Share (Detail)
|
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
|
Sep. 30, 2015
|
Sep. 30, 2014
|
Sep. 30, 2015
|
Sep. 30, 2014
|
|
| Schedule of Weighted Average Number of Diluted Shares Outstanding [Line Items] | ||||
| Weighted average number of ordinary shares outstanding for basic net income per ordinary share | 58,659,782 | 61,878,429 | 59,728,608 | 61,863,332 |
| Effect of dilutive share options outstanding | 1,710,115 | 1,564,178 | 2,057,241 | 1,570,928 |
| Weighted average number of ordinary shares outstanding for diluted net income per ordinary share | 60,369,898 | 63,442,607 | 61,785,849 | 63,434,260 |
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Share-based Awards - Additional Information (Detail) (USD $)
|
9 Months Ended | 9 Months Ended | 9 Months Ended | 9 Months Ended | 9 Months Ended | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2015
|
Sep. 30, 2014
|
Sep. 30, 2015
Employee Stock Plan, 2008 Plan
|
Sep. 30, 2015
Employee Stock Plan, 2008 Plan
Individual Employee
|
Sep. 30, 2015
Employee Stock Plan, 2008 Plan
Minimum
|
Sep. 30, 2015
Employee Stock Plan, 2003 Plan
|
Sep. 30, 2015
Employee Stock Plan, 2003 Plan
Individual Employee
|
Sep. 30, 2015
Employee Stock Option
|
Sep. 30, 2014
Employee Stock Option
|
Dec. 31, 2014
Employee Stock Option
|
Sep. 30, 2015
Employee Stock Option
Minimum
|
Sep. 30, 2015
Employee Stock Option
Maximum
|
Sep. 30, 2015
Restricted Stock Units 2008
|
Apr. 23, 2013
Restricted Stock Units 2013
|
Sep. 30, 2015
Performance Share Unit (PSUs)
|
Dec. 31, 2014
Performance Share Unit (PSUs)
|
Sep. 30, 2015
Performance Share Unit (PSUs)
Vest Upon the Achievement of EPS Performance Targets
|
|
| Compensation Related Costs Share Based Payments Disclosure [Line Items] | |||||||||||||||||
| Percentage of option price for fair value of ordinary share | 100.00% | ||||||||||||||||
| Ordinary shares which have been reserved for issuance | 6,000,000 | 400,000 | 6,000,000 | 400,000 | 1,000,000 | 1,600,000 | |||||||||||
| Maximum number of award as percentage of shares outstanding | 10.00% | ||||||||||||||||
| Shares vesting period | 5 years | 3 years | |||||||||||||||
| Shares expiration period | 8 years | ||||||||||||||||
| Contractual term of options outstanding | 4 years 10 months 6 days | 8 years | |||||||||||||||
| Options outstanding fair value | $ 5.88 | $ 19.78 | |||||||||||||||
| Weighted average fair value per option | $ 11.91 | $ 10.40 | |||||||||||||||
| Exercisable - number of shares | 695,902 | ||||||||||||||||
| Exercisable - weighted average remaining contractual life | 3 years 6 months 4 days | ||||||||||||||||
| Exercisable - weighted average exercise price | $ 25.19 | ||||||||||||||||
| Fully vested total intrinsic value | $ 31,900,000 | ||||||||||||||||
| Intrinsic value of option exercised | 30,500,000 | 18,200,000 | |||||||||||||||
| Shares expected to vest - number of shares | 467,991 | ||||||||||||||||
| Outstanding - number of shares | 936,418 | 669,171 | |||||||||||||||
| Non-cash stock compensation expense not yet recognized | 57,700,000 | ||||||||||||||||
| Unrecognized stock-based compensation expense, weighted average period (years) | 2 years 6 months | ||||||||||||||||
| Tax benefit on exercise of options | $ 3,014,000 | $ 1,800,000 | |||||||||||||||
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected to Vest, Number No definition available.
|
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Option Price No definition available.
|
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement by Share Based Payment Award, Options, Weighted Average Grant Date Fair Value No definition available.
|
| X | ||||||||||
|
- Definition
Amount of increase in additional paid in capital (APIC) resulting from a tax benefit associated with share-based compensation plan other than an employee stock ownership plan (ESOP). Includes, but is not limited to, excess tax benefit. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Unrecognized cost of unvested share-based compensation awards. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock. No definition available.
|
| X | ||||||||||
|
- Definition
Purchase price of common stock expressed as a percentage of its fair value. No definition available.
|
|
Summary of Stock Option Activity (Detail) (Employee Stock Option, USD $)
|
9 Months Ended | |
|---|---|---|
|
Sep. 30, 2015
|
Sep. 30, 2014
|
|
|
Employee Stock Option
|
||
| Options Outstanding Number of Shares | ||
| Outstanding at beginning of period | 2,227,700 | |
| Granted | 259,059 | |
| Exercised | (686,467) | |
| Forfeited | (64,842) | |
| Outstanding at end of period | 1,735,450 | |
| Exercisable at end of period | 695,902 | |
| Weighted Average Exercise Price | ||
| Outstanding at beginning of period | $ 28.00 | |
| Granted | $ 68.25 | |
| Exercised | $ 26.58 | |
| Forfeited | $ 24.59 | |
| Outstanding at end of period | $ 34.64 | |
| Exercisable at end of period | $ 25.19 | |
| Weighted Average Fair Value | ||
| Outstanding at beginning of period | $ 10.40 | |
| Granted | $ 19.75 | $ 15.51 |
| Exercised | $ 10.18 | |
| Forfeited | $ 9.48 | |
| Outstanding at end of period | $ 11.91 | |
| Exercisable at end of period | $ 9.71 | |
| Weighted Average Remaining Contractual Life | ||
| Outstanding at end of period | 4 years 10 months 6 days | |
| Exercisable at end of period | 3 years 6 months 4 days | |
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement by Share Based Payment Award, Forfeited in Period, Weighted Average Grant Date Fair Value No definition available.
|
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement by Share Based Payment Award, Options, Exercisable, Weighted Average Grant Date Fair Value No definition available.
|
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Weighted Average Grant Date Fair Value No definition available.
|
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement by Share Based Payment Award, Options, Weighted Average Grant Date Fair Value No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Net number of share options (or share units) granted during the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Number of options outstanding, including both vested and non-vested options. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Weighted average price at which option holders acquired shares when converting their stock options into shares. No definition available.
|
| X | ||||||||||
|
- Definition
Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. No definition available.
|
| X | ||||||||||
|
- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options. No definition available.
|
| X | ||||||||||
|
- Definition
Number of share options (or share units) exercised during the current period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Summary of Movement in Non-Vested Share Options (Detail) (Employee Stock Option, USD $)
|
9 Months Ended | |
|---|---|---|
|
Sep. 30, 2015
|
Sep. 30, 2014
|
|
|
Employee Stock Option
|
||
| Options Outstanding Number of Shares | ||
| Beginning Balance | 1,203,150 | |
| Granted | 259,059 | |
| Vested | (379,992) | |
| Forfeited | (42,669) | |
| Ending Balance | 1,039,548 | |
| Weighted Average Exercise Price | ||
| Beginning balance | $ 30.54 | |
| Granted | $ 68.25 | |
| Vested | $ 28.25 | |
| Forfeited | $ 25.19 | |
| Ending balance | $ 40.97 | |
| Weighted Average Fair Value | ||
| Beginning Balance | $ 10.98 | |
| Granted | $ 19.75 | $ 15.51 |
| Vested | $ 10.49 | |
| Forfeited | $ 10.20 | |
| Ending Balance | $ 13.38 | |
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement by Share Based Payment Award, Nonvested Options, Forfeited in Period Weighted Average Exercise Price No definition available.
|
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement by Share Based Payment Award, Nonvested Options, Granted in Period Weighted Average Exercise Price No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement by Share Based Payment Award, Nonvested Options, Outstanding Weighted Average Exercise Price No definition available.
|
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement by Share Based Payment Award, Nonvested Options, Vested in Period Weighted Average Exercise Price No definition available.
|
| X | ||||||||||
|
- Definition
Gross number of share options (or share units) granted during the period. No definition available.
|
| X | ||||||||||
|
- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Number of non-vested options outstanding. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Number of non-vested options forfeited. No definition available.
|
| X | ||||||||||
|
- Definition
Weighted average grant-date fair value of non-vested options forfeited. No definition available.
|
| X | ||||||||||
|
- Definition
Weighted average grant-date fair value of non-vested options outstanding. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Number of options vested. No definition available.
|
| X | ||||||||||
|
- Definition
Weighted average grant-date fair value of options vested. No definition available.
|
|
Schedule of Weighted Average Fair Values and Assumptions Used (Detail) (Employee Stock Option, USD $)
|
9 Months Ended | |
|---|---|---|
|
Sep. 30, 2015
|
Sep. 30, 2014
|
|
|
Employee Stock Option
|
||
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
| Weighted average fair value | $ 19.75 | $ 15.51 |
| Assumptions: | ||
| Expected volatility | 30.00% | 31.00% |
| Dividend yield | 0.00% | 0.00% |
| Risk-free interest rate | 1.58% | 1.66% |
| Expected life | 5 years | 5 years |
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The risk-free interest rate assumption that is used in valuing an option on its own shares. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Summary of RSU and PSU Activity (Detail) (USD $)
|
9 Months Ended |
|---|---|
|
Sep. 30, 2015
|
|
|
Performance Share Unit (PSUs)
|
|
| Outstanding Number of Shares | |
| Outstanding at beginning of period | 669,171 |
| Granted | 283,394 |
| Forfeited | (16,147) |
| Outstanding at ending of period | 936,418 |
| Weighted Average Fair Value | |
| Outstanding at beginning of period | $ 39.78 |
| Granted | $ 68.06 |
| Forfeited | $ 42.73 |
| Outstanding at end of period | $ 48.34 |
| Weighted Average Remaining Contractual Life | |
| Outstanding at end of period | 1 year 8 months 19 days |
|
Restricted Stock Units (RSUs)
|
|
| Outstanding Number of Shares | |
| Outstanding at beginning of period | 1,038,996 |
| Granted | 383,169 |
| Shares vested | (227,805) |
| Forfeited | (61,555) |
| Outstanding at ending of period | 1,132,805 |
| Weighted Average Fair Value | |
| Outstanding at beginning of period | $ 35.19 |
| Granted | $ 66.94 |
| Shares vested | $ 25.32 |
| Forfeited | $ 41.85 |
| Outstanding at end of period | $ 47.55 |
| Weighted Average Remaining Contractual Life | |
| Outstanding at end of period | 1 year 8 months 1 day |
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Schedule of Non-cash Stock Compensation Expense (Detail) (USD $)
In Thousands, unless otherwise specified |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
|
Sep. 30, 2015
|
Sep. 30, 2014
|
Sep. 30, 2015
|
Sep. 30, 2014
|
|
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
| Share-based compensation expense | $ 9,031 | $ 6,645 | $ 24,043 | $ 16,396 |
|
Direct costs
|
||||
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
| Share-based compensation expense | 4,976 | 3,661 | 12,942 | 9,034 |
|
Selling, general and administrative
|
||||
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
| Share-based compensation expense | $ 4,055 | $ 2,984 | $ 11,101 | $ 7,362 |
| X | ||||||||||
|
- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
|
Share Capital - Additional Information (Detail) (Buyback Program, USD $)
|
3 Months Ended | |||
|---|---|---|---|---|
|
Sep. 30, 2015
|
Jun. 30, 2015
|
Jul. 31, 2015
|
May 01, 2015
|
|
|
Buyback Program
|
||||
| Equity, Class of Treasury Stock [Line Items] | ||||
| Stock repurchase program, authorized amount | $ 400,000,000 | $ 60,000,000 | ||
| Ordinary shares redeemed | 2,904,170 | 882,419 | ||
| Ordinary shares redeemed, value | $ 229,500,000 | $ 58,200,000 | ||
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Number of shares that have been repurchased and retired during the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of stock repurchase plan authorized. No definition available.
|
|
Distribution of Net Revenue by Geographical Area (Detail) (USD $)
In Thousands, unless otherwise specified |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
|
Sep. 30, 2015
|
Sep. 30, 2014
|
Sep. 30, 2015
|
Sep. 30, 2014
|
|
| Segment Reporting Information [Line Items] | ||||
| Net Revenue | $ 394,741 | $ 387,589 | $ 1,171,629 | $ 1,113,243 |
|
Ireland
|
||||
| Segment Reporting Information [Line Items] | ||||
| Net Revenue | 113,060 | 99,585 | 332,563 | 273,670 |
|
Rest Of Europe
|
||||
| Segment Reporting Information [Line Items] | ||||
| Net Revenue | 79,077 | 91,350 | 241,705 | 275,881 |
|
United States
|
||||
| Segment Reporting Information [Line Items] | ||||
| Net Revenue | 161,144 | 152,140 | 475,508 | 441,189 |
|
Rest of World
|
||||
| Segment Reporting Information [Line Items] | ||||
| Net Revenue | $ 41,460 | $ 44,514 | $ 121,853 | $ 122,503 |
| X | ||||||||||
|
- Definition
Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
|
Distribution of Income from Operations, including Restructuring and Other Items, by Geographical Area (Detail) (USD $)
In Thousands, unless otherwise specified |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
|
Sep. 30, 2015
|
Sep. 30, 2014
|
Sep. 30, 2015
|
Sep. 30, 2014
|
|
| Segment Reporting Information [Line Items] | ||||
| Income from operations | $ 71,385 | $ 59,423 | $ 206,191 | $ 150,709 |
|
Ireland
|
||||
| Segment Reporting Information [Line Items] | ||||
| Income from operations | 56,612 | 44,022 | 153,620 | 98,892 |
|
Rest Of Europe
|
||||
| Segment Reporting Information [Line Items] | ||||
| Income from operations | 3,871 | 1,121 | 14,178 | 15,492 |
|
United States
|
||||
| Segment Reporting Information [Line Items] | ||||
| Income from operations | 8,129 | 10,871 | 30,576 | 27,211 |
|
Rest of World
|
||||
| Segment Reporting Information [Line Items] | ||||
| Income from operations | $ 2,773 | $ 3,409 | $ 7,817 | $ 9,114 |
| X | ||||||||||
|
- Definition
The net result for the period of deducting operating expenses from operating revenues. No definition available.
|
| X | ||||||||||
|
- Details
|
|
Distribution of Property, Plant and Equipment, Net, by Geographical Area (Detail) (USD $)
In Thousands, unless otherwise specified |
Sep. 30, 2015
|
Dec. 31, 2014
|
|---|---|---|
| Segment Reporting Information [Line Items] | ||
| Property, plant and equipment, net | $ 148,835 | $ 148,185 |
|
Ireland
|
||
| Segment Reporting Information [Line Items] | ||
| Property, plant and equipment, net | 100,076 | 95,574 |
|
Rest Of Europe
|
||
| Segment Reporting Information [Line Items] | ||
| Property, plant and equipment, net | 8,309 | 10,419 |
|
United States
|
||
| Segment Reporting Information [Line Items] | ||
| Property, plant and equipment, net | 33,639 | 33,978 |
|
Rest of World
|
||
| Segment Reporting Information [Line Items] | ||
| Property, plant and equipment, net | $ 6,811 | $ 8,214 |
| X | ||||||||||
|
- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
|
Distribution of Depreciation and Amortization by Geographical Area (Detail) (USD $)
In Thousands, unless otherwise specified |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
|
Sep. 30, 2015
|
Sep. 30, 2014
|
Sep. 30, 2015
|
Sep. 30, 2014
|
|
| Segment Reporting Disclosure [Line Items] | ||||
| Depreciation and amortization | $ 14,366 | $ 13,737 | $ 42,535 | $ 38,207 |
|
Ireland
|
||||
| Segment Reporting Disclosure [Line Items] | ||||
| Depreciation and amortization | 5,144 | 5,171 | 14,972 | 15,577 |
|
Rest Of Europe
|
||||
| Segment Reporting Disclosure [Line Items] | ||||
| Depreciation and amortization | 2,003 | 1,162 | 6,217 | 3,861 |
|
United States
|
||||
| Segment Reporting Disclosure [Line Items] | ||||
| Depreciation and amortization | 6,277 | 6,533 | 18,412 | 16,146 |
|
Rest of World
|
||||
| Segment Reporting Disclosure [Line Items] | ||||
| Depreciation and amortization | $ 942 | $ 871 | $ 2,934 | $ 2,623 |
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Distribution of Total Assets by Geographical Area (Detail) (USD $)
In Thousands, unless otherwise specified |
Sep. 30, 2015
|
Dec. 31, 2014
|
|---|---|---|
| Segment Reporting Information [Line Items] | ||
| Assets | $ 1,812,792 | $ 1,528,850 |
|
Ireland
|
||
| Segment Reporting Information [Line Items] | ||
| Assets | 618,393 | 495,747 |
|
Rest Of Europe
|
||
| Segment Reporting Information [Line Items] | ||
| Assets | 391,883 | 324,086 |
|
United States
|
||
| Segment Reporting Information [Line Items] | ||
| Assets | 746,332 | 648,559 |
|
Rest of World
|
||
| Segment Reporting Information [Line Items] | ||
| Assets | $ 56,184 | $ 60,458 |
| X | ||||||||||
|
- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|